Biogen

Global Personalized Medicines Market to grow from USD 588.31 Million in 2023 to USD 1,007.05 Million by 2031, driven by advancements in genetic technology and rising prevalence of rare diseases. North America leads in demand due to high healthcare expenditure, while Asia-Pacific shows the fastest growth. Market segments include diagnostics, genetic testing, and end-uses like hospitals and diagnostic centers. Key players are investing in R&D and collaborations, and insurance coverage and healthcare budgets are expanding.

Exchange Traded Concepts LLC increased its stake in Biogen Inc. by 4,516.7% in Q3, owning 1,662 shares worth $322,000. Several other investors also increased their holdings, with Vanguard Group Inc. raising its position by 15.0% and owning 16,570,398 shares worth $3.57 billion. Analysts have mixed ratings on Biogen, with a consensus 'Moderate Buy' and a target price of $271.39. Insider Priya Singhal sold 431 shares at $204.22 each, reducing her ownership by 0.00%. Biogen's stock opened at $190.16, with a market cap of $27.69 billion and a PE ratio of 23.74. The company reported $5.28 EPS for Q2, beating estimates by $1.28, with revenue of $2.47 billion.

Cwm LLC reduced its Biogen Inc. position by 12.7% in Q3, selling 480 shares, while several institutional investors increased their holdings. Biogen's stock opened at $190.16 on Friday, with a market cap of $27.69 billion. The company reported $5.28 EPS for Q2, beating estimates, and insiders own 0.16% of the stock. Analysts have mixed ratings, with an average target price of $271.39.

EMA won't renew Translarna's permit; Novartis pays $70M for a cancer drug; Amylyx's AMX0035 shows promise in rare disease; FDA delays Ocaliva approval; Australia rejects Leqembi; Amicus settles with Teva over Galafold.

Sage Therapeutics announces restructuring, laying off 1/3 of workforce & cutting 5 senior execs. This follows FDA approval for Zurzuvae (postpartum depression) but not MDD, & clinical failures in Parkinson’s & Alzheimer’s treatments. Sage plans to prioritize Zurzuvae launch & focus on pipeline development.

Sage Therapeutics to lay off 165 employees, 55% of R&D team, to restructure and focus on Zurzuvae, an FDA-approved oral treatment for postpartum depression. The restructuring aims to strengthen financial and operational positions, incurring $26–28m in Q4 2024. Sage also discontinued dalzanemdor development in Alzheimer’s after Phase II trial failure.

Sage Therapeutics to cut 33% of workforce, focus on postpartum depression drug launch and Huntington's disease study.

With two anti-amyloid Alzheimer’s drugs on the market, investors are focusing on new tests and biomarkers to boost treatment and prevention. The Alzheimer’s Drug Discovery Foundation, backed by billionaires and industry players, has funded companies like C2N Diagnostics and Fujirebio, which are developing more accurate detection methods. The foundation aims to diversify beyond amyloid, focusing on the biology of aging for future Alzheimer’s treatments.

Sage Therapeutics cuts staff, Eisai/Biogen's Leqembi rejected in Australia, Sanofi invests in Orano Med, Novartis licenses Chinese cancer treatment, telehealth's GLP-1 boom driven by select doctor groups, former Trump official calls for IRA revisit, BMS CEO discusses company pivot, Lilly CSO warns against weakening patents, GLP-1s linked to lower opioid overdose risk, Novavax faces vaccine setback.